Written especially for nurses caring for patients with cancer, the 2017 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the 2017 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

New drugs include: alectinib (Alecensa), atezolizumab (Tecentriq), cabozantinib tablets (Cabometyx), cabozantinib capsules (Cometriq), cobimetinib tablets (Cotellic), colistin/polymixin B, clotrimazole, daratumumab (Darzalex), elotuzumab (Empliciti), irinotecan liposome injection (Onivyde), ixazomib (Ninlaro), melphalan for injection (Evoela), necitumumab (Portrazza), osimertinib (Targrisso), pentamidine, posaconazole, peramivir, rolapitant (Varubi) , talimogene laherparepvec (Imlygic), Tamiflu, trabectedin (Yondelis), uridine triacetate (Vistogard granules), venetoclax (Venclexta), vincristine liposome injection (Marqibo), and zanamivir.